Good News for World Kidney Day: GenoMed Can Prevent Most Kidney Failure
GenoMed® (Pink Sheets:GMED), a Next Generation Disease Management company, announced today, World Kidney Day, that it has found drug “recipes” to prevent most kidney failure.
The method was published in a peer-reviewed medical journal in September 2002, but has received little publicity since.
GenoMed’s approach reversed early kidney failure in white, black, and Hispanic patients with diabetes and high blood pressure. Diabetes and high blood pressure cause 90% of kidney failure in the US. Kidney failure affects people of color disproportionately more than whites.
The Centers for Medicaid and Medicare (CMS) currently pay $25 billion annually for kidney dialysis and transplantation. A typical dialysis patient costs $100,000 a year, and lives for less than 3 years on dialysis. When GenoMed’s CEO, Dr. David Moskowitz, briefed CMS about his paper in 2004, the Medical Director and his staff at CMS had no interest. Neither did the National Institutes of Health, nor any non-profit kidney association.
Said Dr. Moskowitz, “In medical school, we were exhorted to find cures. I wouldn’t have believed it then if somebody had told me there was no point in finding a cure because news of the cure would be suppressed. Yet that’s exactly what’s happened for the past four and a half years.”
Dr. Moskowitz continued, “Medicine, like any business, thrives on the status quo. Financially small disruptions can be tolerated, like finding cures for polio and TB in the 1950s. Other than the staff of the polio wards and the TB sanitaria, nobody in medicine was hurt financially. But eliminating 90% of a $25 billion a year industry is another thing altogether. Nobody in healthcare wants their budget or their revenues cut.”
Added Dr. Moskowitz, “This is the real reason why healthcare costs keep rising. Medicine is fundamentally anti-innovative.”
About GenoMed
In addition to avoiding dialysis in chronic kidney failure, GenoMed was also awarded a patent (6,998,404 B2) to treat acute kidney failure without dialysis. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients with early kidney failure are encouraged to contact Dr. Moskowitz about joining GenoMed’s Clinical Outcomes Improvement Program (COIP®).
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,”"should,”"could,”"may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.